May 31,2021

To	To
Listing Department,	The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED	BSE LIMITED
Exchange Plaza,	Phiroz Jeejeebhoy Towers,
Bandra Kurla Complex, Bandra (E),	25th floor, Dalal Street,
MUMBAI -400 051	MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir,

Sub: Audited Financial Results for Fourth Quarter and Year ended March 31, 2021

The Board of Directors of the Company at its meeting held today, May 31,2021, has inter alia, considered and approved:-

the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors. Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, Mis. B S R & Associates LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31,2021 with unmodified opinion.

We also enclose a copy of the Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021.

The Board meeting commenced at 9.00 a.m. and concluded at 12..' ,)-0 p.m.

Please take the information on record.

Yours faithfully, For AUROBINDO PHARMA LIMITED

~,Q-e. .,

B.AdiReddy Company Secretary

Enclosures: as above.

(CIN: L24239TG1986PLC015190) AUROBINDO PHARMA LIMITED PAN No. AABCA7366H

Corp. Off.: Galaxy. Floors: 22·24. Plot No.1 . Survey No.S3/1. Hyderabad Knowledge City. Raidurg Panmaktha. Ranga Reddy District. Hyderabad - 500 032. lelangana.lndia. Tel : +91406672 5000 16672 1200 Fax: +91 4067074044.

RBgd. off.: Plot No.2. Maithrivihar. Ameerpet. Hyderabad· 500 o3B l.S .• INDIA Tel: +91 4023736370/23747340 Fax: +91402374 lOBO 12374 6B33

www.aurobindo.com

AUROBINDO PHARMA LIMITED

(CiN - L24239TG1986PLC015190) Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +9140 23747340; Email: [email protected](Rs. In lakhsl
STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2021
		Quarter ended			Year ended
Particulars	31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
	Audited	Unaudited	Audited	Audited	Audited

1 Revenue from operations
(al Net sales/ income from operations	410,361	372,545	355.235	1,562,218	1,303,882
(bl Other operating income	1,042	972	8,604	20,150	33,195
Total revenue from operations	411,403	373,517	363,839	1,582,368	1,337,077
2 Other income
(al Foreign exchange gain (net) (refer note 7)	3,963	6,433	4,757	18,544	8,767
(b) Others	22,779	9,399	10,893	40,442	15,576
Total other income	26,742	15,832	15,650	58,986	24,343
Total income (1+2)	438,145	389,349	379,489	1,641,354	1,361,420

3 Expenses
(a) Cost of materials consumed	180,316	176,731	180,735	721,573	681,434
(b) Purchase of stock-in-trade	1,502	348	68	2,609	551
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	12,733	(10,064)	(13,002)	299	(23,867)
(d) Employee benefits expense	44,473	43,380	43,441	173,543	157,714
(e) Finance costs	593	586	2,030	2,868	9,791
(f) Depreciation and amortisation expense	12,407	12,221	11,968	48,799	47,333
(g) Other expenses	74,776	65,542	68,679	272,362	251,459
Total expenses	326,800	288,744	293,919	1,222,053	1,124,415

4 Profit before tax (1+2-31	111,345	100,605	85,570	419,301	237,005
5 Tax expense
Current tax	20,898	26,839	18,460	104,334	49,229
Deferred tax	3,189	175	(4,6541	3,676	88
Total tax expense	24,087	27,014	13,806	108,OlD	49,317
6 Profit for the period/year (4-5)	87,258	73,591	71,764	311,291	187,688
7 Other Comprehensive income
Items that will not to be reclassified subsequently to profit or loss:
(a) Re-measurement of defined benefit liability	(254)	(2441	(860)	(986)	(1,952)
(b) Income-tax relating to items that will not be reclassified to profit or loss	88	85	300	344	682

8 Total Comprehensive income for the period/year (6+7)	87,092	73,432	71,204	310,649	186,418
9 Paid-up equity share capital (face value Re. 1 per sharel	5,859	5,859	5,859	5,859	5,859
10 Other equity				1,586,602	1,299,391
11 Earnings per equity share (face value Re. 1 per sharel			(not annualised not annualised (not annualised) ( Annualisedl		( Annualisedl
(al Basic (in Rs.l	14.89	12.56	12.25	53.13	32.03
b) Diluted (in Rs.!	14.89	12.56	1225	53.13	32.03

	St ~dalone balance sheet		IRs. In lakhsl
	SI. PARTICULARS	As at	As at
No.		:11 .0.].20.21	~1 m 2070
		(Audited)	(Audited)

	ASSETS
	1 Non-current assets
	Property, plant and equipment	445,731	440,791
	Capital work-in-progress	71,902	81,485
	Goodwill	699	699
	Intangible assets	776	289
	Intangible assets under development	1,587
	Financial assets
	Investments	488,087	252,739
	Loans	40,152	24,075
	Trade receivables		-
	Other financial assets	11,645	12,894
	Non-current tax assets (net)	12,207	8,453
		8,324	6,105
	Other non-current assets
	Total non-current assets	1,081,110	827,530
	2 Current assets
	Inventories	484,138	435,957
	Financial assets
	Investments	12,904	2
	Trade receivables	592,801	578,500
	Cash and cash equivalents	38,358	8,364
	Bank balances other than cash and cash equivalents	260	253
		1,203	1,220
	Loans
	Other financial assets	6,775	1,774
	Other current assets	101,347	102,761
	Total current assets	1,237,786	1,128,831
	TOTAL ASSETS	2318896	1956.361

	EQUITY AND LIABILITIES
	1 Equity
	Equity share capital	5,859	5,859
	Other equity	1,586,602	1,299,391
	Total equity	1,592,461	1,305,250
	Liabilities
	2 Non-current liabilities
	Financial liabilities
	Other financial liabilities - Lease liabilities	7,442	1,114
	Provisions	-	4,268
	Deferred tax liability (net)	43,338	8,504
	Total non-current liabilities	50,780	13,886

	3 Current liabilities
	Financial liabilities
	Borrowings	395,310	373,032
	Trade payables
	total outstanding dues of micro enterprises and small enterprises and	1,571	4,157
	total outstanding dues of creditors other than micro enterprises and small enterprises	204,521	188,243
	Other financial liabilities	39,603	49,793
	Other current liabilities	9,649	10,473
	Provisions	11,100	11,527
	Current tax liabilities, net	13,901	-
	Total current liablllties	675,655	637,225

	TOTAL EQUITY AND LIABILITIES	2318 896	1956361

	Standalone statement of cash flows		IRs. In (akhs)
51.		For the year	For the year

	No. PARTICULARS	ended	ended
		1 0.'07·	~1m)mO
		(Audited)	{Audited}
	1 CASH FLOW FROM OPERATING ACTIVITIES
	Net profit before tax	419,303	237,OOS
	Adjustments to reconcile profit before tax to net cash flow:

	Depreciation and amoritsation expense	48,799	47,333
	Allowances for doubtful receivables/ provision for advances and other assets (net)	(3,154)	5,367
	Bad debts	23	116
	Provisions no longer required written back	(58)	(11)

	Unrealised foreign exchange gain (net)	(6,244)	(7,031)
	Mark-to-market Gain on derivative financial instruments	(1,901)	223
	Loss on sale of property, plant and equipment (net)	17	240
	Dividend income	(30,746)	(12,592)
	Finance costs		9,362
		2,597
	Interest Income	(4,019)	(1,586)

	Operating profit before working capital changes	424,617	278,426
	Movements in working capitol:

	Increase in trade receivables	(3,459)	(26,958)
	Increase in inventories	(48,181)	(33,153)
	Increase in loans	(110)	(258)
	Increase in other financial assets	(1,218)	(1,975)

	(Increase)/decrease in other current/non-current assets	(331)	9,010
	(Decrease)/increase in trade payables	(2,463)	35,577
	(Decrease)/increase in provision for retirement benefits	(5,681)	1,912
	Decrease in other financial liabilities	(223)	(20)
		(824\	(4,554
	Decrease in other current liabilities
	Cash generated from operating activities	362,127	258,007
	Income-tax paid (net)	(62685	{37869
	Net cash flow generated from operating activities (A)	299,442	220,138

	2 CASH FLOW FROM INVESTING ACTIVITIES
	Purchase of property, plant and equipment including movement in capital work-in-	(39,673)	(68,162)

	progress, capital advances and capital creditors (net)
	(Purchase)/sale of intangible assets under development	(2,217)	3,195

	Proceeds from sale of property, plant and equipment	7,093	1,593
	Purchase of non-current investments	(232,975)	(34,027)
	Purchase of current investments	(12,902)
	Dividend received from subsidiaries	30,746	12,899
	Loans made to subsidiaries	(15,950)	(16,195)

	Loans repaid by subsidiaries	-	4,350
	Interest received	1005	1,179
	Net cash flow used in investing activities (8)	(264,873)	(95,168)

	3 CASH FLOW FROM FINANCING ACTIVITIES

	Proceeds from issuance of equity share capital	-	19
	Repayment of current borrowings (net)	24,316	(97,006)
	Repayment of lease liabilities, net	(1,199)	(882)
	Interest paid	(2,480)	(9,069)

	Dividend paid on equity shares	(23,431)	(17,562)
	Tax paid on equity dividend	-	(966
	Net cash flow used in financing activities (e)	(2,794)	(125,466)

	Net increase In cash and cash equivalents (A+B+C)	31,775	(496)
	Cash and cash equivalents at the beginning of the periodfyear	6,734	6,870

	Effect of exchange differences on cash and cash equivalents	(151)	297
	On business combination	-	63
	Cash and cash equivalents at the end of the period/year	38358	6734


	Cash and cash equivalents comprises of:
	Cash on hand	10	14
	Balance with banks:
	Current accounts	29,508	8,228
	Cash credit accounts (net)	8840	(1508

	Cash and Cash equivalents considered for cash flows	38358	6734

The above statement of cash flows has been prepared under the "Indirect method" as set out in Ind AS 7, "Statement of cash flows".

NOTES:

1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
2 The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 31 May 2021. Th e statutory auditors have carried out audit of the above results for the quarter and year ended 31 March 2021. An unmodified report has been issued by them thereon.
3 The Company operates in only one segment viz., 'Pharmaceutical Products'.
4 Sales of standalone include exports of Rs.356,286Iakhs for the current quarter (31 March 2020: Rs.311,197Iakhs).
5 The Government of India, on 20 September 2019, vide the Taxation laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.
6 During the financial year 2019-20, the Board of directors of the Company has approved for amalgamation of the five subsidiary Companies with Aurobindo Pharma Limited, the holding company with the appointed date of 1 April 2019. Accordingly, a Scheme of Amalgamation for merger of APl Healthcare Limited, APl Research Centre limited, Aurozymes limited, Curepro Parenterals limited, Hyacinths Ph arm a Private limited and Silicon life Sciences Private limited (a stepdown wholly owned subsidiary) with the Company was filed before the Hon'ble National Company law Tribunal, Hyderabad (NClT). Further, during the year, a modified Sclleme Amalgamation was filed with the Hon'ble NClT by way of filing an Interlocutory applica.tion for removal and complete exclusion of the APl Healthcare limited as a party to the Scheme of Amalgamation. The Hon'ble NClT vide order dated 30 March 2021 has approved the modified scheme of amalgamation and a certified copy has been filed by the Company with the Registrar of Companies, Telangana 29 April 2021. Accordingly, the subsidiaries viz. APl Research Centre limited, AUT O~ymes Limited, Curepro Parenterals limited, Hyacinths Pharma Private limited and Silicon life Sciences Private Limited (a stepdown wholly owned subsidiary) have now been merged with Aurobindo Pharma Limited. The appointed date as per the NClT approved Scheme is 1 April 2019, which is the same as the beginning of the preceding period in the financial statements and hence, in line with the Scheme, the combination has been accounted for from that date as per the requirements of Appendix C to Ind AS 103 "Business Combination". Accordingly, the amounts relating to the three months and year ended 31 March 2021 include the impact of tile business combination and the corresponding amounts for three months ended 31 December 2020 and 31 March 2020 and year ended 31 March 2020 shown in the statement, have been restated after recognising the effect of the Scheme as above.

Impact of the Scheme on the statement of standalone results

		Quarter ended Quarter ended	Year ended	Year ended
Particulars	31.12.2020	31.03.2020	31.03.2021	31.03.2020
Total Income	1,766	1,396	7,261	8,972
Total expenses	2,386	3,115	9,812	9,737
Loss before tax	(620)	(1,719)	(2,551)	(765)
Tax expense/(benefit)	(160)	(979)	(657)	(1,179)
Profit/floss) after tax	-.i460	(740\	(1.894	414

7 Foreign exchange gain includes exchange difference of Rs. Nil (31 March 2020: 14,537 lakhs) arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs.
8 The Company continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Company continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. The Company has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on internal and external sources of information, current economic environment and future economic indicators, the Company has assessed the financial impact of the COVI0-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the necessary adjustments if material have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions.
9 The date of implementation of the Code of Wages 2019 and Code on Social Security, 2020 is yet to be notified by the Government. The Company is in the process o( assessing the impact of these Codes and will give effect in the financial results when the Rules/Schemes thereunder are notified.
10 The figures of the quarter ended 31 March 2021 and 31 March 2020 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2021 and 31 March 2020 respectively and the unaudited published year to date figures upto 31 December 2020 and 31 December 2019 respectively, being the date of the end of the third quarter of the financial year. The standalone results for the nine months ended 31 December 2020 and 31 December 2019 have been subjected to the limited review by the statutory auditors.

Place: Hyderabad Date :31 May 2021

N. Govindarajan Managing Director DIN-000S0482

Chartered Accountants

Salarpuriya Knowledge City, Orwell, B Wing, 61h Floor, Unit-3, Sy No. 83/1, Plot No. 02, Raidurg, Hyderabad - 500 081 - India

Telephone: Fax:

+91 4071822000 +91 40 7182 2399

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

Opinion

We have audited the accompanying standalone annual financial results of Aurobindo Pharma Limited (hereinafter referred to as the "Company") for the year ended 31 March 2021, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

INDEPENDENT AUDITOR'S REPORT (continued)

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results (continued)

The Company's Management and Board of Directors are responsible for the preparation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on

INDEPENDENT AUDITOR'S REPORT (continued)

Auditor's Responsibilities for the Audit of the Standalone Financial Results (continued)

whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

INDEPENDENT AUDITOR'S REPORT (continued)

Other Matters

1. The standalone annual financial results include the results for quarter ended 31 March 2021 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
1. The standalone financial results of the company include the financial results of 5 wholly owned subsidiaries whose standalone financial results reflect total assets (before inter-company adjustments) ofRs. 69,855 lakhs as at 31 March 2021 (31 March 2020: Rs. 54,789Iakhs) and the total revenue (before inter-company adjustments) of Rs. 14,627 lakhs (31 March 2020: Rs. 11,091 lakhs) for the year ended on that date. These subsidiaries have been merged with the Company vide The Hon'ble National Company Law Tribunal, Hyderabad order dated 30 March 2021. These subsidiaries have been audited by other auditors whose reports have been furnished to us, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors.

Further, standalone financial results include total revenue (before inter-company adjustments) fOJ: the quarter ended 31 March 2021, 31 March 2020 and 31 December 2020 ofRs. 3,537 lakhs, Rs. 2,825 lakhs and Rs. 4,272 lakhs respectively related to aforesaid subsidiaries. The financial results of the aforesaid subsidiaries for these quarters have not been subjected to review or audit. In our opinion and according to the information and explanations given to us by the Management, the financial results of subsidiaries are not material to the Company.

For B S R & Associates LLP Chartered Accountants ICAl Firm Registration No. 116231W/W-I00024

SRI RAM Digitally signed by SAl RAM MAHALINGAM MAHALINGAM Date: 2021 .05.31 12:40:33 +05'30'

Sriram Mahalingam Partner Membership No: 049642 UDIN: 21049642AAAABR5501

Place: Palakkad Date: 31 May 2021